{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:58:05Z","timestamp":1788404285617,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jgar.2022.12.010","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T11:42:50Z","timestamp":1674042170000},"page":"88-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Oral vs. parenteral antibiotic therapy in adult patients with community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"32","author":[{"given":"Ge-Ling","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yu","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.12.010_bib0001","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/thx.2003.017756","article-title":"Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome","volume":"59","author":"Men\u00e9ndez","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jgar.2022.12.010_bib0003","first-page":"494","article-title":"The incidence rate and economic burden of community-acquired pneumonia in a working-age population","volume":"6","author":"Broulette","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jgar.2022.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMra1312885","article-title":"Community-acquired pneumonia","volume":"371","author":"Musher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.clinthera.2015.04.013","article-title":"Direct medical costs and utilization of health care services to treat pneumonia in the United States: an analysis of the 2007\u20132011 Medical Expenditure Panel Survey","volume":"37","author":"Park","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2022.12.010_bib0006","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3390\/ijms18020447","article-title":"Biomarkers in pediatric community acquired pneumonia","volume":"18","author":"Principi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jgar.2022.12.010_bib0007","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/17476348.2014.896202","article-title":"The management of severe community acquired pneumonia in the intensive care unit","volume":"8","author":"Liapikou","year":"2014","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0008","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.21037\/apm-21-2006","article-title":"Comparison of the community-acquired pneumonia and COVID-19 at the early stage: findings from two cohort studies","volume":"10","author":"Zhang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.resinv.2015.05.003","article-title":"Update on the combination effect of macrolide antibiotics in community-acquired pneumonia","volume":"53","author":"Emmet O\u2019Brien","year":"2015","journal-title":"Respir Investig"},{"key":"10.1016\/j.jgar.2022.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1097\/CCM.0000000000000330","article-title":"Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program","volume":"42","author":"Ferrer","year":"2014","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0011","series-title":"The World Medicines Situation 2011: Rational Use of Medicines","year":"2011"},{"key":"10.1016\/j.jgar.2022.12.010_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/pds.3614","article-title":"Antibiotic therapy for inpatients with community-acquired pneumonia in a developing country","volume":"24","author":"Trinh","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jgar.2022.12.010_bib0013","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1378\/chest.110.4.965","article-title":"A prospective randomized study of inpatient intravenous antibiotics for community-acquired pneumonia: the optimal duration of therapy","volume":"110","author":"Siegel","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2022.12.010_bib0014","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1086\/513953","article-title":"Community acquired pneumonia in adults: guidelines for management","volume":"26","author":"Bartlett","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2022.12.010_bib0016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0002-9343(01)00934-2","article-title":"Oral or intravenous-to-oral antibiotic switch therapy for treating patients with community acquired pneumonia","volume":"111","author":"Cunha","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/adc.2010.205047","article-title":"Question 1 Are oral antibiotics as efficacious as intravenous antibiotics for the treatment of community acquired pneumonia?","volume":"96","author":"Wilder","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jgar.2022.12.010_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0019","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.12.010_bib0020","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","article-title":"The interpretation of random-effects meta analysis in decision models","volume":"25","author":"Ades","year":"2005","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jgar.2022.12.010_bib0021","series-title":"Cochrane Handbook for Systematic Reviews of Interventions 5.0.1","article-title":"Analyzing data and undertaking meta-analyses","author":"Deeks","year":"2008"},{"key":"10.1016\/j.jgar.2022.12.010_bib0022","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.12.010_bib0023","first-page":"15","article-title":"Assessing the influence of a single study in meta-analysis","volume":"47","author":"Tobias","year":"1999","journal-title":"Stata Tech Bull"},{"key":"10.1016\/j.jgar.2022.12.010_bib0024","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.12.010_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.12.010_bib0026","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.jgar.2022.12.010_bib0027","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3109\/00365548709021679","article-title":"Antibiotic therapy in pneumonia: a comparative study of parenteral and oral administration of penicillin","volume":"19","author":"Fredlund","year":"1987","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/26.suppl_E.71","article-title":"Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia","volume":"26","author":"Zuck","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.12.010_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jac\/28.suppl_C.81","article-title":"The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia","volume":"28","author":"Vogel","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.12.010_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/BF02310353","article-title":"Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia","volume":"14","author":"Bohte","year":"1995","journal-title":"Eur J Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2022.12.010_bib0031","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/bmj.310.6991.1360","article-title":"Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomized controlled trial","volume":"310","author":"Chan","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.12.010_bib0032","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0002-9343(01)00868-3","article-title":"Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial","volume":"111","author":"Castro-Guardiola","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0033","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0149-2918(02)80088-1","volume":"24","author":"Lode","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2022.12.010_bib0034","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s10096-003-1060-x","article-title":"Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia","volume":"23","author":"Erard","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0035","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1183\/09031936.04.00143303","article-title":"Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia","volume":"24","author":"Wasserfallen","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2022.12.010_bib0036","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-142-3-200502010-00006","article-title":"Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients","volume":"142","author":"Carratala","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0037","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.diagmicrobio.2007.07.006","article-title":"Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with\/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia","volume":"60","author":"Bhavnani","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0038","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/1574891X13666181024154526","article-title":"Levofloxacin versus ceftriaxone and azithromycin combination in the treatment of community acquired pneumonia in hospitalized patients","volume":"13","author":"Izadi","year":"2018","journal-title":"Recent Pat Antiinfect Drug Discov"},{"key":"10.1016\/j.jgar.2022.12.010_bib0039","first-page":"89","article-title":"A nonparametric \u201ctrim and fill\u201d method for assessing publication bias in meta-analysis","volume":"95","author":"Duvall","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jgar.2022.12.010_bib0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.amjmed.2003.11.013","article-title":"Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis","volume":"116","author":"Marras","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0041","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0042","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1997.00440220040006","article-title":"The hospital admission decision for patients with community-acquired pneumonia","volume":"157","author":"Fine","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0043","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archinte.160.1.98","article-title":"Understanding physician adherence with a pneumonia practice guideline","volume":"160","author":"Halm","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0044","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.12.010_bib0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0002-9343(91)90125-H","article-title":"Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with \u201cusual care\u201d in a multicenter clinical trial","volume":"91","author":"Sanders","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.jgar.2022.12.010_bib0046","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0047","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group","volume":"31","author":"Mandell","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.12.010_bib0048","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.jgar.2022.12.010_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005715","article-title":"Long-term mortality after community-acquired pneumonia: impacts of diabetes and newly discovered hyperglycaemia: a prospective, observational cohort study","volume":"4","author":"Koskela","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jgar.2022.12.010_bib0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/resp.12324","article-title":"Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study","volume":"19","author":"Ferrer","year":"2014","journal-title":"Respirology"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:12Z","timestamp":1761991212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":50,"alternative-id":["S2213716523000036"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.12.010","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral vs. parenteral antibiotic therapy in adult patients with community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}